SG169404A1 - Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(r)-2- hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl) ethylamino]methyl]}-5- methoxyphenylcarbamoyl)ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders - Google Patents

Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(r)-2- hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl) ethylamino]methyl]}-5- methoxyphenylcarbamoyl)ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders

Info

Publication number
SG169404A1
SG169404A1 SG201100933-9A SG2011009339A SG169404A1 SG 169404 A1 SG169404 A1 SG 169404A1 SG 2011009339 A SG2011009339 A SG 2011009339A SG 169404 A1 SG169404 A1 SG 169404A1
Authority
SG
Singapore
Prior art keywords
hydroxy
methoxyphenylcarbamoyl
dihydroquinolin
piperidin
ethylamino
Prior art date
Application number
SG201100933-9A
Other languages
English (en)
Inventor
Reshma Chudasama
Andrew Kennedy
Leanda Jane Kindon
Franck Patrick Mallet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36119909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG169404(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SG169404A1 publication Critical patent/SG169404A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG201100933-9A 2006-02-10 2007-02-08 Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(r)-2- hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl) ethylamino]methyl]}-5- methoxyphenylcarbamoyl)ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders SG169404A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0602778.3A GB0602778D0 (en) 2006-02-10 2006-02-10 Novel compound

Publications (1)

Publication Number Publication Date
SG169404A1 true SG169404A1 (en) 2011-03-30

Family

ID=36119909

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201100933-9A SG169404A1 (en) 2006-02-10 2007-02-08 Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(r)-2- hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl) ethylamino]methyl]}-5- methoxyphenylcarbamoyl)ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders

Country Status (33)

Country Link
US (1) US7960551B2 (enExample)
EP (1) EP1981872B1 (enExample)
JP (1) JP5616021B2 (enExample)
KR (1) KR101488691B1 (enExample)
CN (1) CN101379057B (enExample)
AR (2) AR059409A1 (enExample)
AU (1) AU2007213767B2 (enExample)
BR (1) BRPI0707559B8 (enExample)
CA (1) CA2641769C (enExample)
CR (1) CR10227A (enExample)
CY (1) CY1119238T1 (enExample)
DK (1) DK1981872T3 (enExample)
EA (1) EA016580B1 (enExample)
ES (1) ES2640226T3 (enExample)
GB (1) GB0602778D0 (enExample)
HR (1) HRP20171304T1 (enExample)
HU (1) HUE034315T2 (enExample)
IL (1) IL193103A (enExample)
JO (1) JO3389B1 (enExample)
LT (1) LT1981872T (enExample)
MA (1) MA30273B1 (enExample)
MY (1) MY153656A (enExample)
NO (1) NO341343B1 (enExample)
NZ (1) NZ570242A (enExample)
PE (2) PE20110120A1 (enExample)
PL (1) PL1981872T3 (enExample)
PT (1) PT1981872T (enExample)
SG (1) SG169404A1 (enExample)
SI (1) SI1981872T1 (enExample)
TW (1) TWI401251B (enExample)
UA (1) UA100364C2 (enExample)
WO (1) WO2007090859A1 (enExample)
ZA (1) ZA200806782B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2758353C (en) * 2009-04-14 2017-06-06 Dean David Edney Process for the preparation of a biphenyl-2-ylcarbamic acid ester
ES2417339T3 (es) 2009-04-23 2013-08-07 Theravance, Inc. Compuestos de diamina que tienen actividad antagonista del receptor muscarinico y agonista del receptor beta2-adrenergico
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) * 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
ES2729549T3 (es) * 2011-08-02 2019-11-04 Alfasigma Spa Composición farmacéutica de avidina oxidada adecuada para la inhalación
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EA201500651A1 (ru) * 2012-12-18 2015-11-30 Альмираль, С.А. НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
CN106632257B (zh) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 Gsk961081及其中间体的合成方法
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026897A (en) 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4894219A (en) 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
EP0640081B1 (en) 1992-03-31 2000-01-12 Glaxo Group Limited Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-ht4 antagonists
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
EP0747355A4 (en) 1994-02-10 1997-04-09 Yamanouchi Pharma Co Ltd NEW CARBAMATES AND MEDICINAL PRODUCTS CONTAINING THEM
WO1997013766A1 (en) 1995-10-13 1997-04-17 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
WO1999031086A1 (en) 1997-12-12 1999-06-24 Smithkline Beecham Plc Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
SG80041A1 (en) 1998-06-08 2001-04-17 Advanced Medicine Inc Muscarinic receptor antagonists
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
JP2003516390A (ja) 1999-12-07 2003-05-13 セラヴァンス インコーポレーテッド ムスカリンレセプターアンタゴニスト活性を有するカルバメート誘導体
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
PL358057A1 (en) 2000-06-05 2004-08-09 Altana Pharma Ag Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors
KR100869722B1 (ko) 2000-12-22 2008-11-21 알미랄 에이쥐 퀴누클리딘 카르바메이트 유도체 및 ｍ3 길항제로서 그의사용
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
ES2248767T3 (es) 2002-04-12 2006-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Medicamento que contiene beta-mimeticos y un nuevo anticolinergico.
AU2003239880A1 (en) 2002-05-28 2003-12-12 Theravance, Inc. ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1615881A2 (en) 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
ATE435862T1 (de) 2003-05-28 2009-07-15 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY

Also Published As

Publication number Publication date
EP1981872A1 (en) 2008-10-22
AU2007213767A1 (en) 2007-08-16
ES2640226T3 (es) 2017-11-02
CN101379057A (zh) 2009-03-04
TWI401251B (zh) 2013-07-11
BRPI0707559B8 (pt) 2021-05-25
JP2009526018A (ja) 2009-07-16
KR101488691B1 (ko) 2015-02-02
JP5616021B2 (ja) 2014-10-29
SI1981872T1 (sl) 2017-10-30
TW200800948A (en) 2008-01-01
NO341343B1 (no) 2017-10-16
NO20083425L (no) 2008-09-09
PE20110120A1 (es) 2011-03-08
LT1981872T (lt) 2017-09-11
EP1981872B1 (en) 2017-06-21
PL1981872T3 (pl) 2017-11-30
AR059409A1 (es) 2008-04-09
WO2007090859A1 (en) 2007-08-16
EA200801691A1 (ru) 2009-02-27
BRPI0707559A2 (pt) 2011-05-10
AR104288A2 (es) 2017-07-12
CA2641769A1 (en) 2007-08-16
CY1119238T1 (el) 2018-02-14
KR20080114723A (ko) 2008-12-31
IL193103A (en) 2013-06-27
PE20071249A1 (es) 2008-01-16
CN101379057B (zh) 2013-02-13
GB0602778D0 (en) 2006-03-22
CA2641769C (en) 2014-02-04
DK1981872T3 (en) 2017-09-11
IL193103A0 (en) 2009-02-11
HRP20171304T1 (hr) 2017-10-20
ZA200806782B (en) 2009-10-28
BRPI0707559B1 (pt) 2021-01-12
BRPI0707559A8 (pt) 2019-01-29
HUE034315T2 (en) 2018-02-28
UA100364C2 (xx) 2012-12-25
US7960551B2 (en) 2011-06-14
AU2007213767B2 (en) 2012-04-26
EA016580B1 (ru) 2012-06-29
PT1981872T (pt) 2017-09-13
MA30273B1 (fr) 2009-03-02
NZ570242A (en) 2011-09-30
JO3389B1 (ar) 2019-03-13
US20070281971A1 (en) 2007-12-06
CR10227A (es) 2008-10-29
MY153656A (en) 2015-03-13

Similar Documents

Publication Publication Date Title
SG169404A1 (en) Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(r)-2- hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl) ethylamino]methyl]}-5- methoxyphenylcarbamoyl)ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders
TW200613296A (en) Crystalline form of a biphenyl compound
IL192241A0 (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)-benzamides and the salts thereof
WO2010088518A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
BRPI0906104A2 (pt) "derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto"
PL1951279T3 (pl) Kompstatyna i jej analogi w zaburzeniach oczu
ZA201007805B (en) Solid pharmaceutical formulations comprising bibw 2992
HUE039108T2 (hu) Készítmények és eljárások szembetegségek kezelésére
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
EP2083862A4 (en) COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND DISORDERS
EP1996218A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
IL223126A (en) METHOD FOR PREPARING 5,4-DIETOXYCY-TETRAYDROFORAN-2-IL-METHYL ESTER ACETIC ACID AND THE SPACIAL ISOMERS
EP2277861A4 (en) CYCLIC AMIN-1-CARBOXYLIC ACID EST DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREWITH
EP1968943A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF MONTELUCASTAST AND THE PHARMACEUTICALLY SAFE SALTS
EP2025667A4 (en) 9, 10-SECOPREGNANDERIVAT AND MEDICINAL PRODUCTS
EP2119436A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF EYE DISEASES
EP2069307A4 (en) PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS
IL205981A0 (en) 15,16-METHYLENE-17-HYDROXY-19-NOR-21-CARBOXYLIC ACID ã?-LACTONE DERIVATIVE , USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE
IL215550A (en) Process for the preparation of a biphenyl ester 2-carboxylic acid moiety 1– [2–2] -chloro-4-formyl-5-methoxyphenyl) -carbamoylethyl] piperidene-4 ester yl and intermediate
IL198875A0 (en) Piperidine derivative used for treating chemokine receptor 5 mediated diseases
TH82585A (th) โครงรูปผลึกของสารประกอบไบฟีนิล
HK1136280A (en) Piperidine derivative used for treating chemokine receptor 5 mediated diseases
HK1133652A (en) Piperidine derivative used for treating chemokine receptor 5 mediated diseases
HUP0600726A3 (en) N-(phenalkylamino-alkyl)-carboxylic acid amides, process for their preparation, their use and pharmaceutical compositions containing the same
GB0608646D0 (en) Radiused curtain pole (for tab top curtains)